Current commercial insulin formulations do not possess the most desirable onset of action since the duration of time from injection to peak activity can be up to 3 h [1] . This makes it difficult to match insulin administration with meals, and may increase the risk of postprandial hypoglycaemia [2] . One of the limitations in absorption of subcutaneously administered insulin is the rate of dissociation of hexamer to dimer (and possibly monomer) at the injection site [3] . Therefore, insulin analogues that self-associate more weakly than human insulin would be anticipated to act more rapidly [4] . This has been demonstrated clinically with insulin analogues such as Lys B28 Pro B29 insulin [5, 6] and Asp B10 insulin [7] . Structure/function studies employing insulin analogues have suggested that amino acid residues in insulin essential for insulin receptor binding affinity include Gly , and Phe B24 -Tyr B26 [8, 9] . Truncation of the insulin B chain sequentially from the C-terminal end does not significantly reduce insulin binding until Tyr B26 is removed, generating des-(B26-30) insulin (despentapeptide Diabetologia (1997) 40: S 54-S 61 Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor Summary Inversion of the natural sequence of the B chain of human insulin (HI) from Pro B28 Lys B29 to Lys B28 Pro B29 generates an insulin analogue with reduced tendency to self-associate. Since this substitution increases the homology of insulin to insulin-like growth factor-I (IGF-I), we have examined the affinity of a series of insulin analogues with the general modified structure Xaa B28 Pro B29 HI for binding to both human placental insulin and IGF-I receptors. The Xaa ). Combination of Asp B10 substitution in conjunction with a modification in the B28-29 position (e.g.
Asp
B10 Lys B28 Pro B29 HI) showed an additional 2-fold selective increase in affinity for the IGF-I receptor, suggesting that these two effects are additive. Addition of Arg residues at B31-32, on the backbone of either HI or Asp B10 HI, increased affinity for the IGF-I receptor 10 and 28 fold, respectively, compared to HI, confirming the significance of enhanced positive charge at the C-terminal end of the insulin B-chain in increasing selectivity for the IGF-I receptor. This relative increase in IGF-I receptor affinity correlated largely, but not completely, with enhanced growth promoting activity in human mammary epithelial cells. In the case of Lys insulin, or DPI) with approximately 20-50 % the activity of insulin [10, 11] . However, DPI-Phe B25 amide has full potency [12] . This would suggest that the B26-30 region is not particularly critical for insulin receptor recognition. However, it is clearly important in mediating the formation of insulin dimers [13, 14] . For this reason, structural modifications of insulin in this region would be anticipated to generate monomeric insulin analogues with minimal alteration in insulin receptor affinity. Insulin-like growth factor I (IGF-I) is a 70-amino acid polypeptide which induces proliferation and differentiation in a number of cell types [15] . IGF-I is a single-chain molecule with A and B domains that exhibit 45-50 % homology with the A and B chains of insulin. Unlike insulin, however, the A and B regions of IGF-I are connected through a 12-residue C domain and the C-terminal end of the A domain contains an 8-residue D region extension. The IGF-I and insulin receptors also exhibit substantial structural homology to each another, and both ligands have weak, but measurable, affinity for the heterologous receptor [15] .
Early studies with insulin/IGF-I mixed hybrid molecules (e. g. A IGF-I -B Insulin ) suggested that the A domain of IGF-I possessed most of the selectivity for the IGF-I receptor [16] . However, more recent studies employing site-directed mutants of IGF-I have demonstrated that substitution of residues 42-56 in the IGF-I A domain with the homologous residues of insulin had no effect on IGF-I receptor affinity [17] . Several studies have suggested that the key regions of IGF-I responsible for inducing selectivity for the type I receptor are located in the C region and the C-terminal portion of the B domain [18, 19] .
Homology of the C-terminal region of the B chain of insulin with the corresponding regions of IGF-I (and the closely related molecule IGF-II) is enhanced in Lys B28 Pro B29 insulin and Arg B28 Pro B29 insulin, respectively (Fig. 1) . For this reason, we investigated the relative affinities of the entire Xaa B28 Pro B29 insulin series compared to human insulin for binding to the human placental insulin and IGF-I receptors to determine if these analogues possessed differential affinity for the two receptors.
Materials and methods
Materials. Insulin analogues were made by either: 1) recombinant DNA methods; 2) trypsin-catalysed semisynthesis in a mixed organic solvent system [20] using des-(B23-30) forms of porcine insulin and Asp B10 human insulin, and the corresponding synthetic octapeptide modified in the B28-29 positions [21] ; or 3) chain combination [22] using recombinant human insulin A chain with a synthetic B chain. Arg B31 Arg B32 (DiArg) insulin and Asp
B10
DiArg insulin were obtained by limited tryptic hydrolysis of recombinant human proinsulin and Asp B10 human proinsulin, respectively. tert-Butoxycarbonyl (Boc) amino acids were purchased from Applied Biosystems (Foster City, Calif., USA). All other chemicals were of analytical grade or higher. Natural sequence human IGF-I was of recombinant DNA origin (Lilly). Iodinations were performed by the lactoperoxidase procedure, and in the case of insulin or insulin analogues, the Tyr A14 monoiodinated species (specific activity approximately 360 m Ci/mg) was employed [23] . Protein was determined by the BCA (bicinchoninic acid) method (Pierce Chemical, Rockford, Ill., USA) using bovine serum albumin (BSA) as standard. Placental membranes were obtained from full term human placenta by a modification of the procedure of Grupusso et al. [24] . RIA-grade BSA was obtained from Sigma (St. Louis, Mo., USA). HepG2 cells were obtained from the American Type Tissue Collection (Rockville, Md., USA).
Cell growth. Mitogenicity was assessed by measuring insulin analogue-stimulated growth of human mammary epithelial cells (HMEC) in culture. HMEC were obtained from Clonetics Corporation (San Diego, Calif., USA) at passage 7 and were expanded and frozen at passage 8. A fresh ampule was used for each experiment so that cells were not grown beyond passage 9. Cells were maintained in MCDB 170 medium containing bovine insulin (5 m g/ml), recombinant human epidermal growth factor (10 ng/ml), hydrocortisone (0.5 m g/ml bovine insulin was substituted by a graded dose of human insulin or analogue from 0 to 1000 nmol/l final concentration. Trays were incubated for 72 h and the cells were counted by Coulter counter (Coulter Electronics, Hialeah, Fla., USA) after trypsinization. Typically, the maximal growth response was between 3-and 4-fold stimulation over basal and did not differ between analogues. Response data were normalized to between 0 and 100 % response equal to 100 × (response at dose X -response at zero dose) divided by (response at maximal dose -response at zero dose). Dose-response data were fit by non-linear regression employing JMP (SAS Institute, Inc., Cary, N. C., USA). 
Pro
B29 HI, and -Asp B10 HI were obtained according to the method of Drejer et al. [25] .
Results
Placental insulin and IGF-I receptor binding. Table 1 shows the EC 50 values for binding of the Xaa residues, as well as the entire terminal tripeptide also had little effect. Interestingly, Gly B29 was only marginally less potent than native insulin compared to the 50 % reduction in activity observed with the Gly B28 substitution. Analysis of the same analogue series in the IGF-I receptor binding assay suggested that the IGF-I receptor was more sensitive to changes in the B28-B29 region than was the insulin receptor. IGF-I receptor affinity was reduced in the same series of B28-substituted aliphatic and aromatic analogues as observed with the insulin receptor (Xaa = Gly, Ile, Leu, Phe or Trp), but also with Xaa = Ala, Pro and Val, but, interestingly, not Met. The presence of charged residues in the B28 position of Xaa B28 Pro B29 insulin was of particular interest, since basic residues (Xaa = Arg, Lys and Orn) appeared to slightly increase IGF-I receptor affinity, while acidic residues (Xaa = Asp, Cya and Glu) reduced binding affinity. The more basic Arg residue enhances IGF-I receptor affinity to a greater extent than does either of the less basic Lys or Orn residues. The acidic residue substitutions appear to follow a similar order, with the more acidic Cya showing the greater effect. Interestingly, the simple removal of Pro B28 resulted in a 2.3-fold enhancement in IGF-I receptor affinity, while the Gly B29 and Ala B26 substitutions reduced affinity by 50-60 %.
None of these analogues had significantly altered affinity for the insulin receptor. The sequential effect of substitution in the B28-29 position is shown in Figure 2 , where the affinity of native insulin for both the insulin and IGF-I receptors has been set to 100 %. Replacing Pro B28 of insulin with Lys (Lys B28 Lys B29 insulin) increases the relative IGF-I receptor affinity almost 2.5-fold, while additional substitution of Lys B29 with Pro (Lys B28 Pro B29 insulin) reduces the affinity increase by approximately 35 %. This is quantitatively similar to the reduction in IGF-I receptor affinity observed when comparing insulin to Pro B28 Pro B29 insulin, which again reflects the effect of a Lys B29 to Pro B29 substitution. This suggests that the more important modulator of the altered IGF-I receptor affinity is the charged residue in the 28 position, not the B29 Pro.
To assess further the effect of altered positive charge in this region on IGF-I receptor affinity, Arg-
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B32 insulin (DiArg insulin) was examined. This molecule possesses two additional Arg residues at the C-terminal end of the insulin B chain, and, in fact, is a naturally occurring intermediate in the biosynthetic processing of proinsulin to insulin. Although previous studies have indicated that DiArg insulin is approximately equipotent with native insulin in terms of insulin receptor binding and stimulation of glucose uptake into adipocytes [26] , we found in the present study that DiArg insulin is approximately 1.5-times more potent than insulin in the placental insulin receptor binding assay (Table 2 ). However, it was found to be 10.2 times more potent than insulin at displacing [ Substitution of Asp for His at B10 increased IGF-I receptor affinity to an extent similar to that reported previously for binding to the insulin receptor [27] , and this effect was additive when added onto a background of Xaa B28 Pro B29 insulin with Xaa = Asp, Lys or Val (Table 2) . Superimposing the Asp B10 substitution on top of the Arg B31 Arg B32 addition resulted in a 28-fold increase in IGF-I receptor affinity relative to insulin, again showing that substitutions in these two regions are additive (Table 2) . This was further supported by the analogue series generated from sequential truncation of the C-terminal five amino acids on top of the Asp B10 substitution. Removal of Thr B30 (leaving a terminal Lys) increased affinity for the IGF-I receptor to a greater extent than it did for the insulin receptor, while removal of Lys B29 (leaving a terminal Pro) resulted in a 60 % decrease in affinity for the IGF-I receptor compared to a 30 % reduction for the insulin receptor. Interestingly, complete truncation to Asp 
Human mammary epithelial cells (HMEC) growth and IGF-I receptor binding.
Several key insulin analogues from the above-mentioned series were examined in terms of their ability to stimulate growth of normal human mammary epithelial cells. These cells were chosen because they can readily be cultured under defined medium conditions and insulin (or IGF-I) is a required growth factor. Table 3 and Figure 3 summarize the EC 50 values and relative potencies for these analogues. When all analogues were considered, relative potency in the mitogenicity assay correlated highly with placental IGF-I receptor binding activity (p < 0.01), but not insulin receptor affinity, suggesting that it is largely an IGF-I receptor-mediated event. Table 3 also shows binding data for these analogues to the HMEC IGF-I receptor. Characterization of the HMEC insulin and IGF-I receptors by LIGAND [28] indicated a very low level of insulin receptor compared to IGF-I receptor (2200 vs 44 000 receptors/ cell, respectively). HI, 14 %; Asp B10 HI, 0 %. These data suggest that increased degradation of Lys B28 Pro B29 HI compared to insulin is not sufficient to be responsible for artifactually altering their relative potencies in this assay.
Alternatively, De Meyts et al. [31] and Hansen et al. [32] have suggested that mitogenicity of insulin analogues may be associated with residency time on the insulin receptor such that higher mitogenic activity would correlate with slower dissociation kinetics. 
).
Discussion
The results of this study indicate that despite the high sequence homology between insulin and IGF-I, their respective receptors recognize the C-terminal portion of the B chain and extensions into the C chain quite differently. The inversion of the B28 proline to the B29 position in the Xaa B28 Pro B29 insulin analogues series had little effect on insulin receptor selectivity, unless large aliphatic or aromatic residues were present at the B28 position. Binding to the IGF-I receptor, however, showed much greater sensitivity to structural changes in this region. This sensitivity was not only to steric bulk, but also to charge, since comparison of an Arg at B28 to a Glu at the same position resulted in a greater than 5-fold difference in placental IGF-I receptor affinity with no change in insulin receptor binding. -NH 2 insulin [33] have been reported to show 7-10 times greater affinity than insulin for the insulin receptor, but no apparent selectivity for the IGF-I receptor.
It is interesting to note that an Arg-Arg sequence exists in the C domain of IGF-I. It has been reported that substitution of the Arg 36 Arg 37 residues of IGF-I by Ala reduces IGF-I receptor affinity 15-fold, confirming the importance of this portion of the C domain in mediating IGF-I receptor selectivity [34] . Interestingly, substitution of Lys 65 and Lys 68 in the D region with Ala also reduced IGF-I receptor affinity approximately 10-fold, suggesting that multiple basic residues (Lys 27 , Arg Rutter [35] demonstrated that 56 and 52 amino acid stretches in the cysteine-rich regions of the insulin and IGF-I receptors, respectively, contained major determinants for ligand binding specificity. Others have confirmed the importance of the cysteine-rich region of the IGF-I receptor in ligand specificity [36] [37] [38] , but have suggested that the N-terminal 68 amino acid portion of the insulin receptor a -subunit contains the key residues for insulin selectivity [38] . It is interesting to note that the C-terminal 20 amino acids of the region of the IGF-I receptor described by Gustafson and Rutter contains one basic residue and five acidic residues, which might interact with the essential basic residues on IGF-I.
In general, analogue potency in stimulation of HMEC growth correlated with IGF-I receptor binding affinity. This is in contrast to previous reports which suggested that Asp B10 HI is considerably more potent in growth assays than would be predicted by its relative affinity to either the insulin or IGF-I receptor [32, 39, 40] . Whether this is due to differences between assays (measurement of [ 3 H] thymidine incorporation vs actual increase in cell number) or differences between cell types used is unclear. Although we cannot rule out involvement of the insulin receptor, the dramatic enhancement in mitogenic activity of Asp B10 DiArg HI compared to its relatively modest increase in insulin receptor affinity would suggest that the IGF-I receptor is involved in the mitogenic response for at least the more potent analogues. Lys B28 Pro B29 HI, which has slightly increased IGF-I receptor binding affinity relative to insulin in both the placental and HMEC binding assays, was indistinguishable from insulin in the HMEC cell growth assay. Since this does not appear to be entirely an artifact of decreased stability of Lys B28 Pro B29 HI compared to insulin during the duration of the assay, several explanations are possible. First, the precision of the growth assay was insufficient to resolve small differences (1.5−2-fold) in relative potency. This seems unlikely, since the assay did resolve insulin and Ala B26 HI, whose activity in both the IGF-I receptor and growth assay was 50 % that of insulin. Alternatively, as suggested by Hansen et al. [32] , the mitogenic activity of insulin analogues may be inversely proportional to their dissociation rate from the insulin receptor, even in the presence of a large excess of IGF-I receptors. This is particularly striking when the analogue k d is less than 25 % that of insulin [32] . Since the dissociation rate constants for insulin and Lys B28 Pro B29 HI are identical, this could explain their equivalence in the HMEC growth assay.
The potential increase in IGF-I activity in insulin analogues recently became an important issue when Asp B10 insulin was found to be associated with an increased incidence of breast tumours in rats during 12-month toxicity studies [41, 42] and was subsequently removed from clinical trials. Since several in vitro studies have shown that Asp B10 HI has enhanced growth promoting activity compared to insulin [32, 39, 40] , it has been speculated that this is the mechanism behind the observed mammary tumours [41] . However, independent 12-month toxicity studies with Gly A21 Arg B31 Arg B32 HI [43] , which would be expected to have enhanced IGF-I receptor affinity as a result of the DiArg substitution, and with Lys B28-Pro B29 HI [44] have not demonstrated an association with breast tumours. These results would suggest that in vitro mitogenic activity or IGF-I receptor binding affinity per se do not appear to correlate with increased tumour incidence in vivo.
In summary, we have demonstrated that the IGF-I receptor exhibits greater selectivity for charge differences in the C-terminal portion of the B chain of insulin than does the insulin receptor. This may be due to the importance of basic residues in positions Lys 27 , Arg 36 , Arg 37 , Lys 65 and Lys 68 of IGF-I, some of which have been previously shown to be critical for IGF-I receptor affinity [34] . In general, analogues with substantially increased IGF-I receptor affinity are more potent in stimulating HMEC growth. However, with certain insulin analogues of only marginally enhanced IGF-I receptor affinity, such as Lys B28 Pro B29 human insulin, no enhanced mitogenicity relative to human insulin is observed, suggesting that IGF-I receptor binding and mitogenicity do not completely correlate.
